Denmark - Pharmaceutical products

Description

Procurement No: 1ATC Code: A04AA01Generic name: OndansetronePharmaceutical form: Injection FluidStrength: 2 mg/mlPackage: 2 mlUnit value: 16 mgVolume in units: (Iceland: 1029) (Norway: 50000) (Denmark: 93478).The above pharmaceuticals are put up for tender independently of the pharmaceuticals under the other procurement numbers.Each procurement number is considered a separate lot. A supplier may thus choose to submit tender for 1, several or all procurement numbers, and award will take place separately for each individual procurement number. Reference is made to the tender specifications, including the provisions on submission of tender under the individual procurement numbers.Under the title “quantity in units”, an estimated consumption of the pharmaceuticals is indicated for each of the countries.It should be noted that this estimate is based on historic consumption data and that the suppliers must expect that the actual purchase under a Framework Agreement may differ significantly from the estimate. Reference is made to Paragraph 3.6 of the tender specifications and Clause 2 of the Framework Agreement.The supplier must have authorisation to produce, import or receive pharmaceuticals for wholesale distribution within the EU/EEA.Marketing authorisations applicable for Denmark, Norway and Iceland must be in place for the pharmaceuticals in sufficient time to ensure that the pharmaceuticals appear in Medicinpriser.dk (Denmark), “Farmalogg” (Norway) and “Lyfjaverðskrá” (Iceland) no later than 1.12.2019. The requirement regarding and “Lyfjaverðskrá” (Iceland) only apply if Iceland is part of the Framework Agreement, see Section II.2.11). Procurement No: 2ATC Code: A04AA01Generic name: OndansetronePharmaceutical form: Injection FluidStrength: 2 mg/mlPackage: 4 mlUnit value: 16 mgVolume in units: (Iceland: 329) (Norway: 15000) (Denmark: 16625).The above pharmaceuticals are put up for tender independently of the pharmaceuticals under the other procurement numbers.Each procurement number is considered a separate lot. A supplier may thus choose to submit tender for 1, several or all procurement numbers, and award will take place separately for each individual procurement number. Reference is made to the tender specifications, including the provisions on submission of tender under the individual procurement numbers.Under the title “quantity in units”, an estimated consumption of the pharmaceuticals is indicated for each of the countries.It should be noted that this estimate is based on historic consumption data and that the suppliers must expect that the actual purchase under a Framework Agreement may differ significantly from the estimate. Reference is made to Paragraph 3.6 of the tender specifications and Clause 2 of the Framework Agreement.The supplier must have authorisation to produce, import or receive pharmaceuticals for wholesale distribution within the EU/EEA.Marketing authorisations applicable for Denmark, Norway and Iceland must be in place for the pharmaceuticals in sufficient time to ensure that the pharmaceuticals appear in Medicinpriser.dk (Denmark), “Farmalogg” (Norway) and “Lyfjaverðskrá” (Iceland) no later than 1.12.2019. The requirement regarding and “Lyfjaverðskrá” (Iceland) only apply if Iceland is part of the Framework Agreement, see Section II.2.11). Procurement No: 3ATC Code: J01GB03Generic name: GentamicinPharmaceutical form: Infusion FluidStrength: 1 mg/mlUnit value: 0,24 gVolume in units: (Iceland: 47) (Norway: 6667) (Denmark: 903)The above pharmaceuticals are put up for tender independently of the pharmaceuticals under the other procurement numbers.Each procurement number is considered a separate lot. A supplier may thus choose to submit tender for 1, several or all procurement numbers, and award will take place separately for each individual procurement number. Reference is made to the tender specifications, including the provisions on submission of tender under the individual procurement numbers.Under the title “quantity in units”, an estimated consumption of the pharmaceuticals is indicated for each of the countries.It should be noted that this estimate is based on historic consumption data and that the suppliers must expect that the actual purchase under a Framework Agreement may differ significantly from the estimate. Reference is made to Paragraph 3.6 of the tender specifications and Clause 2 of the Framework Agreement.The supplier must have authorisation to produce, import or receive pharmaceuticals for wholesale distribution within the EU/EEA.Marketing authorisations applicable for Denmark, Norway and Iceland must be in place for the pharmaceuticals in sufficient time to ensure that the pharmaceuticals appear in Medicinpriser.dk (Denmark), “Farmalogg” (Norway) and “Lyfjaverðskrá” (Iceland) no later than 1.12.2019. The requirement regarding “Lyfjaverðskrá” (Iceland) only apply if Iceland is part of the framework agreement, see Section II.2.11). Procurement No: 4ATC Code: J01GB03Generic name: GentamicinPharmaceutical form: Infusion FluidStrength: 3 mg/mlPackage: 80 mlUnit value: 0,24 gVolume in units: (Iceland: 60) (Norway: 33000) (Denmark: 4750).The above pharmaceuticals are put up for tender independently of the pharmaceuticals under the other procurement numbers.Each procurement number is considered a separate lot. A supplier may thus choose to submit tender for 1, several or all procurement numbers, and award will take place separately for each individual procurement number. Reference is made to the tender specifications, including the provisions on submission of tender under the individual procurement numbers.Under the title “quantity in units”, an estimated consumption of the pharmaceuticals is indicated for each of the countries.It should be noted that this estimate is based on historic consumption data and that the suppliers must expect that the actual purchase under a Framework Agreement may differ significantly from the estimate. Reference is made to Paragraph 3.6 of the tender specifications and Clause 2 of the Framework Agreement.The supplier must have authorisation to produce, import or receive pharmaceuticals for wholesale distribution within the EU/EEA.Marketing authorisations applicable for Denmark, Norway and Iceland must be in place for the pharmaceuticals in sufficient time to ensure that the pharmaceuticals appear in Medicinpriser.dk (Denmark), “Farmalogg” (Norway) and “Lyfjaverðskrá” (Iceland) no later than 1.12.2019. The requirement regarding “Lyfjaverðskrá” (Iceland) only apply if Iceland is part of the framework agreement, see Section II.2.11). Procurement No: 5ATC Code: J01GB03Generic name: GentamicinPharmaceutical form: Infusion FluidStrength: 3 mg/mlPackage: 120 mlUnit value: 0,24 gVolume in units: (Iceland: 64) (Norway: 39000) (Denmark: 17205).The above pharmaceuticals are put up for tender independently of the pharmaceuticals under the other procurement numbers.Each procurement number is considered a separate lot. A supplier may thus choose to submit tender for 1, several or all procurement numbers, and award will take place separately for each individual procurement number. Reference is made to the tender specifications, including the provisions on submission of tender under the individual procurement numbers.Under the title “quantity in units”, an estimated consumption of the pharmaceuticals is indicated for each of the countries.It should be noted that this estimate is based on historic consumption data and that the suppliers must expect that the actual purchase under a Framework Agreement may differ significantly from the estimate. Reference is made to Paragraph 3.6 of the tender specifications and Clause 2 of the Framework Agreement.The supplier must have authorisation to produce, import or receive pharmaceuticals for wholesale distribution within the EU/EEA.Marketing authorisations applicable for Denmark, Norway and Iceland must be in place for the pharmaceuticals in sufficient time to ensure that the pharmaceuticals appear in Medicinpriser.dk (Denmark), “Farmalogg” (Norway) and “Lyfjaverðskrá” (Iceland) no later than 1.12.2019. The requirement regarding “Lyfjaverðskrá” (Iceland) only apply if Iceland is part of the framework agreement, see Section II.2.11). Procurement No: 6,ATC Code: N02BE01Generic name: ParacetamolPharmaceutical form: Infusion FluidStrength: 10 mg/mlPackage: 10-50 mlUnit value: 3 gVolume in units: (Iceland: 1) (Norway: 21667) (Denmark: 1817).The above pharmaceuticals are put up for tender independently of the pharmaceuticals under the other procurement numbers.Each procurement number is considered a separate lot. A supplier may thus choose to submit tender for 1, several or all procurement numbers, and award will take place separately for each individual procurement number. Reference is made to the tender specifications, including the provisions on submission of tender under the individual procurement numbers.Under the title “quantity in units”, an estimated consumption of the pharmaceuticals is indicated for each of the countries.It should be noted that this estimate is based on historic consumption data and that the suppliers must expect that the actual purchase under a Framework Agreement may differ significantly from the estimate. Reference is made to Paragraph 3.6 of the tender specifications and Clause 2 of the Framework Agreement.The supplier must have authorisation to produce, import or receive pharmaceuticals for wholesale distribution within the EU/EEA.Marketing authorisations applicable for Denmark, Norway and Iceland must be in place for the pharmaceuticals in sufficient time to ensure that the pharmaceuticals appear in Medicinpriser.dk (Denmark), “Farmalogg” (Norway) and “Lyfjaverðskrá” (Iceland) no later than 1.12.2019. The requirement regarding “Lyfjaverðskrá” (Iceland) only apply if Iceland is part of the Framework Agreement, see Section II.2.11). Procurement No: 7ATC Code: N02BE01Generic name: ParacetamolPharmaceutical form: Infusion FluidStrength: 10 mg/mlPackage: 100 mlUnit value: 3 gVolume in units: (Iceland: 880) (Norway: 21667) (Denmark: 10688).The above pharmaceuticals are put up for tender independently of the pharmaceuticals under the other procurement numbers.Each procurement number is considered a separate lot. A supplier may thus choose to submit tender for 1, several or all procurement numbers, and award will take place separately for each individual procurement number. Reference is made to the tender specifications, including the provisions on submission of tender under the individual procurement numbers.Under the title “quantity in units”, an estimated consumption of the pharmaceuticals is indicated for each of the countries.It should be noted that this estimate is based on historic consumption data and that the suppliers must expect that the actual purchase under a Framework Agreement may differ significantly from the estimate. Reference is made to Paragraph 3.6 of the tender specifications and Clause 2 of the Framework Agreement.The supplier must have authorisation to produce, import or receive pharmaceuticals for wholesale distribution within the EU/EEA.Marketing authorisations applicable for Denmark, Norway and Iceland must be in place for the pharmaceuticals in sufficient time to ensure that the pharmaceuticals appear in Medicinpriser.dk (Denmark), “Farmalogg” (Norway) and “Lyfjaverðskrá” (Iceland) no later than 1.12.2019. The requirement regarding “Lyfjaverðskrá” (Iceland) only apply if Iceland is part of the Framework Agreement, see Section II.2.11).

Opportunity closing date

21 May 2019

Value of contract

£5m-50m